Literature DB >> 31873964

Interval brain imaging for adults with cerebral glioma.

Gerard Thompson1, Theresa A Lawrie2, Ashleigh Kernohan3, Michael D Jenkinson4.   

Abstract

BACKGROUND: Clinical practice guidelines suggest that magnetic resonance imaging (MRI) of the brain should be performed at certain time points or intervals distant from diagnosis (interval or surveillance imaging) of cerebral glioma, to monitor or follow up the disease; it is not known, however, whether these imaging strategies lead to better outcomes among patients than triggered imaging in response to new or worsening symptoms.
OBJECTIVES: To determine the effect of different imaging strategies (in particular, pre-specified interval or surveillance imaging, and symptomatic or triggered imaging) on health and economic outcomes for adults with glioma (grades 2 to 4) in the brain. SEARCH
METHODS: The Cochrane Gynaecological, Neuro-oncology and Orphan Cancers (CGNOC) Group Information Specialist searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase up to 18 June 2019 and the NHS Economic Evaluation Database (EED) up to December 2014 (database closure). SELECTION CRITERIA: We included randomised controlled trials, non-randomised controlled trials, and controlled before-after studies with concurrent comparison groups comparing the effect of different imaging strategies on survival and other health outcomes in adults with cerebral glioma; and full economic evaluations (cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses) conducted alongside any study design, and any model-based economic evaluations on pre- and post-treatment imaging in adults with cerebral glioma. DATA COLLECTION AND ANALYSIS: We used standard Cochrane review methodology with two authors independently performing study selection and data collection, and resolving disagreements through discussion. We assessed the certainty of the evidence using the GRADE approach. MAIN
RESULTS: We included one retrospective, single-institution study that compared post-operative imaging within 48 hours (early post-operative imaging) with no early post-operative imaging among 125 people who had surgery for glioblastoma (GBM: World Health Organization (WHO) grade 4 glioma). Most patients in the study underwent maximal surgical resection followed by combined radiotherapy and temozolomide treatment. Although patient characteristics in the study arms were comparable, the study was at high risk of bias overall. Evidence from this study suggested little or no difference between early and no early post-operative imaging with respect to overall survival (deaths) at one year after diagnosis of GBM (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.61 to 1.21; 48% vs 55% died, respectively; very low certainty evidence) and little or no difference in overall survival (deaths) at two years after diagnosis of GBM (RR 1.06, 95% CI 0.91 to 1.25; 86% vs 81% died, respectively; very low certainty evidence). No other review outcomes were reported. We found no evidence on the effectiveness of other imaging schedules. In addition, we identified no relevant economic evaluations assessing the efficiency of the different imaging strategies. AUTHORS'
CONCLUSIONS: The effect of different imaging strategies on survival and other health outcomes remains largely unknown. Existing imaging schedules in glioma seem to be pragmatic rather than evidence-based. The limited evidence suggesting that early post-operative brain imaging among GBM patients who will receive combined chemoradiation treatment may make little or no difference to survival needs to be further researched, particularly as early post-operative imaging also serves as a quality control measure that may lead to early re-operation if residual tumour is identified. Mathematical modelling of a large glioma patient database could help to distinguish the optimal timing of surveillance imaging for different types of glioma, with stratification of patients facilitated by assessment of individual tumour growth rates, molecular biomarkers and other prognostic factors. In addition, paediatric glioma study designs could be used to inform future research of imaging strategies among adults with glioma.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31873964      PMCID: PMC6953319          DOI: 10.1002/14651858.CD013137.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  76 in total

1.  Impact of imaging measurements on response assessment in glioblastoma clinical trials.

Authors:  David A Reardon; Karla V Ballman; Jan C Buckner; Susan M Chang; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

2.  Challenges to Treating Older Glioblastoma Patients: the Influence of Clinical and Tumour Characteristics on Survival Outcomes.

Authors:  C F Lorimer; C Hanna; F Saran; A Chalmers; J Brock
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-08-12       Impact factor: 4.126

3.  Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study.

Authors:  C P Geer; J Simonds; A Anvery; M Y Chen; J H Burdette; M E Zapadka; T L Ellis; S B Tatter; G J Lesser; M D Chan; K P McMullen; A J Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-24       Impact factor: 3.825

4.  Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Authors:  J C Easaw; W P Mason; J Perry; N Laperrière; D D Eisenstat; R Del Maestro; K Bélanger; D Fulton; D Macdonald
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

Review 5.  The management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm.

Authors:  Ashish H Shah; Karthik Madhavan; Deborah Heros; Daniel M S Raper; J Bryan Iorgulescu; Brian E Lally; Ricardo J Komotar
Journal:  Neurosurg Focus       Date:  2011-12       Impact factor: 4.047

6.  Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.

Authors:  Yan Li; Janine M Lupo; Mei-Yin Polley; Jason C Crane; Wei Bian; Soonmee Cha; Susan Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2011-02-04       Impact factor: 12.300

7.  The role of surveillance magnetic resonance imaging (MRI) scanning in detecting recurrent brain tumors in asymptomatic children.

Authors:  D N Korones; R Butterfield; S P Meyers; L S Constine
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

8.  Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.

Authors:  Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2011-04-28       Impact factor: 12.531

Review 9.  Epidemiology of brain tumors.

Authors:  Hiroko Ohgaki
Journal:  Methods Mol Biol       Date:  2009

Review 10.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more
  10 in total

1.  Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

Authors:  So Young Ji; Jongjin Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong Hwy Kim; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Yongdai Kim; Chul-Kee Park
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

Review 2.  Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Authors:  Catherine McBain; Theresa A Lawrie; Ewelina Rogozińska; Ashleigh Kernohan; Tomos Robinson; Sarah Jefferies
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04

3.  Trophinin-associated protein expression correlates with shorter survival of patients with glioma: a study based on multiple data fusion analysis.

Authors:  Yong Sun; Zhen Dong Liu; Run Ze Liu; Xiao Yu Lian; Xing Bo Cheng; Yu Long Jia; Bin Feng Liu; Yan Zheng Gao; Xinjun Wang
Journal:  Mol Biol Rep       Date:  2022-06-16       Impact factor: 2.742

Review 4.  Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.

Authors:  Jasmin Jo; Martin J van den Bent; Burt Nabors; Patrick Y Wen; David Schiff
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

Review 5.  High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.

Authors:  Otto M Henriksen; María Del Mar Álvarez-Torres; Patricia Figueiredo; Gilbert Hangel; Vera C Keil; Ruben E Nechifor; Frank Riemer; Kathleen M Schmainda; Esther A H Warnert; Evita C Wiegers; Thomas C Booth
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 5.738

6.  Medical student experience with robot-assisted surgery after limited laparoscopy exposure.

Authors:  Nasit Vurgun; Tanawat Vongsurbchart; Aneta Myszka; Piotr Richter; Tomasz Rogula
Journal:  J Robot Surg       Date:  2020-07-23

Review 7.  A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research.

Authors:  Thomas C Booth; Gerard Thompson; Helen Bulbeck; Florien Boele; Craig Buckley; Jorge Cardoso; Liane Dos Santos Canas; David Jenkinson; Keyoumars Ashkan; Jack Kreindler; Nicky Huskens; Aysha Luis; Catherine McBain; Samantha J Mills; Marc Modat; Nick Morley; Caroline Murphy; Sebastian Ourselin; Mark Pennington; James Powell; David Summers; Adam D Waldman; Colin Watts; Matthew Williams; Robin Grant; Michael D Jenkinson
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

8.  A Radiomics Model for Predicting Early Recurrence in Grade II Gliomas Based on Preoperative Multiparametric Magnetic Resonance Imaging.

Authors:  Zhen-Hua Wang; Xin-Lan Xiao; Zhao-Tao Zhang; Keng He; Feng Hu
Journal:  Front Oncol       Date:  2021-09-02       Impact factor: 6.244

9.  Validation of the portable virtual reality training system for robotic surgery (PoLaRS): a randomized controlled trial.

Authors:  Anton Kooijmans; Tim Horeman; Sem F Hardon; Roel Horeman; Maarten van der Elst; Alexander L A Bloemendaal
Journal:  Surg Endosc       Date:  2021-12-06       Impact factor: 3.453

10.  Imaging timing after glioblastoma surgery (INTERVAL-GB): protocol for a UK and Ireland, multicentre retrospective cohort study.

Authors:  Conor S Gillespie; Emily R Bligh; Michael T C Poon; Georgios Solomou; Abdurrahman I Islim; Mohammad A Mustafa; Ola Rominiyi; Sophie T Williams; Neeraj Kalra; Ryan K Mathew; Thomas C Booth; Gerard Thompson; Paul M Brennan; Michael D Jenkinson
Journal:  BMJ Open       Date:  2022-09-13       Impact factor: 3.006

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.